Vectors and methods to treat ischemia
OwnerJan Nolta, Karen Pepper +2inventors
InventorsJan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
Life of this patent
Estimating the term…
Abstract
This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
Claims15
A method for treating peripheral artery disease and/or critical limb ischemia in a patient in need thereof comprising administering to the patient an effective amount of an isolated marrow stromal cell comprising a lentiviral vector, wherein the vector comprises:
- (a) a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof, and
- (b) a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF or an equivalent thereof.
A method for promoting wound healing, promoting or increasing the rate of angiogenesis or wound healing, decreasing the size of a wound, or decreasing the time to wound healing in a patient in need thereof comprising administering to the patient an effective amount of an isolated marrow stromal cell comprising a lentiviral vector, wherein the vector comprises:
- (a) a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof, and
- (b) a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF or an equivalent thereof.
A method for salvaging a limb in a patient with peripheral artery disease or critical limb ischemia comprising administering to the patient an effective amount an isolated marrow stromal cell comprising a lentiviral vector to a patient in need thereof, wherein the vector comprises:
- (a) a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof, and
- (b) a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF or an equivalent thereof.
A method for increasing vascularization in a patient in need thereof comprising administering to the patient an effective amount of an isolated marrow stromal cell comprising a lentiviral vector, wherein the vector comprises:
- (a) a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof, and
- (b) a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF or an equivalent thereof.
An isolated marrow stromal cell expresses the marker phenotype CD34−/CD45−/CD105+/CD90+/CD73+, or the marker phenotype CD105+/CD90+/CD73+, wherein the cell comprises a lentiviral vector, and wherein the vector comprises:
- (a) a nucleic acid encoding a 165A isoform VEGF protein or an equivalent thereof, and
- (b) a promoter that regulates expression of the nucleic acid encoding the 165A isoform VEGF or an equivalent thereof.
Dependencies are inferred from the claim text.